A 52-year-old man with a 10-year history of chronic pancreatitis presents with steatorrhea, weight loss, and fat-soluble vitamin deficiencies. Fecal elastase-1 is 185 U/g (normal >200). Abdominal ultrasound shows pancreatic atrophy with ductal dilation. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **chronic pancreatitis with pancreatic exocrine insufficiency** (PEI), evidenced by: - Steatorrhea and weight loss (malabsorption) - Fecal elastase-1 = 185 U/g (borderline low; <200 U/g indicates PEI) - Imaging findings consistent with chronic pancreatitis ## Management of Pancreatic Exocrine Insufficiency **Key Point:** Once PEI is diagnosed (by fecal elastase, 72-hour fecal fat, or secretin test), the cornerstone of management is **pancreatic enzyme replacement therapy (PERT)**, not further diagnostic testing or endoscopic intervention. ### Why PERT is First-Line | Feature | PERT | ERCP | Octreotide | |---------|------|------|------------| | **Indication** | All PEI patients | Ductal obstruction, stones, strictures | Refractory diarrhea, pain (adjunct only) | | **Mechanism** | Replaces lost pancreatic enzymes | Relieves mechanical obstruction | Reduces pancreatic secretion | | **Evidence** | Improves malabsorption, weight gain | For obstructive disease | Not for enzyme deficiency | | **Timing** | Immediate after diagnosis | Only if obstruction present | Adjunctive role | **High-Yield:** The fecal elastase-1 threshold of 200 U/g is the diagnostic cutoff; values 200–500 suggest mild insufficiency, <200 confirms moderate-to-severe PEI. This patient meets criteria for PERT initiation. ### Dosing Strategy - Start with 25,000–40,000 units of lipase per meal (with food) - Titrate upward based on symptom response (reduction in steatorrhea, weight gain) - Typical maintenance: 40,000–80,000 units per meal - Acid suppression (PPI) often added to protect enzymes in the stomach **Clinical Pearl:** ERCP is reserved for obstructive disease (ductal stones, strictures, pseudocysts) and is NOT indicated for simple enzyme deficiency. Octreotide is an adjunct for pain or refractory diarrhea, not primary therapy for malabsorption. ## Why This Patient Needs PERT Now 1. Fecal elastase confirms PEI (borderline low) 2. Clinical symptoms (steatorrhea, weight loss) are active 3. No imaging evidence of ductal obstruction requiring ERCP 4. PERT addresses the underlying pathophysiology (enzyme replacement) **Mnemonic:** **PERT-First** — Pancreatic Exocrine Replacement Therapy is the first-line management once insufficiency is confirmed; diagnostic tests (secretin) are for diagnosis, not management.